公开(公告)号：US20240358858A1

公开(公告)日：2024-10-31

申请号：US18577797

申请日：2022-08-26

Applicant: The Hong Kong University of Science and Technology

Inventor： Hiu Tung Cheung ,  Wenshu Zeng

IPC: A61K48/00 ,  A61K38/17 ,  A61P21/00 ,  C12N5/0775 ,  G01N33/50

CPC classification number: A61K48/0058 ,  A61K38/1709 ,  A61P21/00 ,  C12N5/0668 ,  G01N33/5061 ,  G01N2333/4704 ,  G01N2800/7042

Abstract: Compositions and methods are provided for the assessment and treatment of age-related conditions and diseases. Also provided are methods for identifying compounds that can potentially regulate the aging process.

公开(公告)号：US20240358857A1

公开(公告)日：2024-10-31

申请号：US18559078

申请日：2022-05-11

Applicant: REGENXBIO INC.

Inventor： Olivier Danos ,  SunJung Kim ,  Nicolas Buss ,  Michele Fiscella ,  Ye Liu ,  Chunping Qiao

IPC: A61K48/00 ,  A61K38/17 ,  A61K45/06 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A61K38/1709 ,  A61K45/06 ,  C12N15/86 ,  C12N2750/14143

Abstract: Provided are methods of treating or ameliorating the symptoms of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy by administration of therapeutically effective doses of recombinant adeno-associated viruses (rAAV) containing a transgene encoding a microdystrophin in combination with a second therapeutic which is effective to treat or ameliorate the symptoms of the dystrophinopathy.

公开(公告)号：US20240350585A1

公开(公告)日：2024-10-24

申请号：US18760628

申请日：2024-07-01

Applicant: Albert BURGIN

Inventor： Albert BURGIN

IPC: A61K38/17 ,  A23L33/00 ,  A23L33/17 ,  A23L33/21

CPC classification number: A61K38/1709 ,  A23L33/17 ,  A23L33/21 ,  A23L33/40 ,  A61K38/1703

Abstract: Methods are described for preparing a protein-enriched soluble fiber composition in granular form, and the use of the product in edible foodstuffs and beverages.

公开(公告)号：US20240350581A1

公开(公告)日：2024-10-24

申请号：US18288813

申请日：2022-04-29

Applicant: THE UNIVERSITY OF WESTERN ONTARIO

Inventor： Michael STRONG ,  Cristian DROPPELMANN ,  Kathryn VOLKENING ,  Danae CAMPOS-MELO ,  Hind AMZIL

IPC: A61K38/17 ,  A61P25/28 ,  C12N15/113

CPC classification number: A61K38/1709 ,  A61P25/28 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/31

Abstract: A method for reducing, inhibiting, preventing or treating cytotoxicity in a cell, the method comprising expressing or overexpressing in the cell a Rho guanine nucleotide exchange factor (RGNEF), or a RGNEF analog or agonist, or a leucine rich domain of RGNEF, whereby the cytotoxicity in the cell is reduced, inhibited, prevented or treated. Also a method of shifting the survival curve of a subject and thereby increasing life expectancy of the subject by administering to the subject a physiologically effective amount of a peptide comprising A Rho Guanine Nucleotide Exchange Factor (RGNEF) protein, or a RGNEF analog or agonist, or a leucine rich domain of RGNEF, or expressing or overexpressing RGNEF or a RGNEF analog or agonist or a leucine rich domain of RGNEF in the subject.

公开(公告)号：US20240342312A1

公开(公告)日：2024-10-17

申请号：US18580421

申请日：2022-08-03

Applicant: Baylor College of Medicine

Inventor： Todd Rosengart ,  Jayapratap Pinnamaneni ,  Vivek P. Singh ,  Jiangchang Yang

IPC: A61K48/00 ,  A61K38/17 ,  A61K38/18 ,  A61K45/06 ,  A61P9/04 ,  C07K14/82 ,  C07K16/18 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A61K38/1709 ,  A61K38/1866 ,  A61K45/06 ,  A61K48/0033 ,  A61K48/0075 ,  A61P9/04 ,  C07K14/82 ,  C07K16/18 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2740/15043

Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63-TID and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5, and/or one or more of ETV2 and VEGF. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63-TID and one or both of the transcription factors Hand2 and myocardin.

公开(公告)号：US20240335506A1

公开(公告)日：2024-10-10

申请号：US18294048

申请日：2022-08-04

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： John A. Chiorini ,  Matthew P. Hoffman

IPC: A61K38/17 ,  A61K48/00 ,  A61N5/10 ,  A61P1/00 ,  C12N15/86

CPC classification number: A61K38/1709 ,  A61K48/0033 ,  A61K48/0075 ,  A61P1/00 ,  C12N15/86 ,  A61N5/10 ,  C12N2750/14143

Abstract: Administration of aquaporin-1 (AQP1) complementary deoxyribonucleic acid (cDNA) to a salivary gland prior to treatment with ionizing radiation (IR) prevents the subsequent IR-induced loss in function. The administration of AQPI (e.g., human AQP1: hAQP1) prior to IR treatment (e.g., in patients with head and neck cancer) can reduce or prevent IR-induced salivary hypofunction, resulting in an elevated salivary output.

公开(公告)号：US20240325490A1

公开(公告)日：2024-10-03

申请号：US18437974

申请日：2024-02-09

Applicant: Research & Business Foundation Sungkyunkwan University

Inventor： Jee Yin AHN ,  lnwoo HWANG ,  Byeong Seong KIM

IPC: A61K38/17 ,  A61K48/00 ,  A61P9/10 ,  A61P25/28

CPC classification number: A61K38/1709 ,  A61K48/0033 ,  A61P9/10 ,  A61P25/28

Abstract: Disclosed is a pharmaceutical composition, containing ErbB3-binding protein 1 (EBP1) protein or a polynucleotide encoding Ebp1 protein as an active ingredient, for preventing and treating ischemic cerebrovascular disease, wherein the pharmaceutical composition has excellent effect of suppressing neuronal damage caused by ischemia by promoting mitophagy and thus can be advantageously used as an agent for preventing or treating ischemic cerebrovascular disease.

公开(公告)号：US12104195B2

公开(公告)日：2024-10-01

申请号：US18326505

申请日：2023-05-31

Applicant: Amorepacific Corporation

Inventor： Phil June Park ,  Hyunsoo Kim ,  Dong Hyun Kim

IPC: A61K8/64 ,  A61K36/258 ,  A61K38/17 ,  C07K16/22 ,  C12P21/00

CPC classification number: C12P21/005 ,  A61K8/64 ,  A61K36/258 ,  A61K38/1709 ,  C07K16/22 ,  A61K2800/85

Abstract: Provided are a reelin and/or VEGF-C production and/or activation promoter including a compound represented by Chemical Formula 1 and/or a ginseng extract containing the compound, as an active ingredient, and a skin external composition including the same.




In Chemical Formula 1, each substituent is as defined in the specification.

公开(公告)号：US20240310359A1

公开(公告)日：2024-09-19

申请号：US18595964

申请日：2024-03-05

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Eun Hui LEE ,  Jun Hee CHOI ,  Seung Yeon JEONG ,  Jooho KIM

IPC: G01N33/50 ,  A61K38/17 ,  A61P21/00

CPC classification number: G01N33/502 ,  A61K38/1709 ,  A61P21/00 ,  G01N33/5061 ,  G01N2333/4703 ,  G01N2500/10 ,  G01N2800/10

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a skeletal muscle disease, a method of screening a drug for the treatment of a skeletal muscle disease, a composition for diagnosing a skeletal muscle disease, and a method of providing information for the diagnosis of a skeletal muscle disease.

公开(公告)号：US20240309098A1

公开(公告)日：2024-09-19

申请号：US18667130

申请日：2024-05-17

Applicant: ACCELERON PHARM INC.

Inventor： John Knopf ,  Ravindra Kumar ,  Asya Grinberg ,  Robert Scott Pearsall ,  Dianne S. Sako ,  Roselyne Castonguay ,  Gang Li ,  Yossi Dagon

IPC: C07K16/28 ,  A61K38/17 ,  C07K14/71 ,  C12N9/12

CPC classification number: C07K16/2863 ,  A61K38/1709 ,  A61K38/177 ,  C07K14/71 ,  C12N9/1205 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/10 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these alk7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.